Výsledky vyhľadávania - "Chemotherapy, Adjuvant / methods"

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Autori: Uppaluri, Ravindra Haddad, Robert I Tao, Yungan a ďalší

Zdroj: New England Journal of Medicine. 393:37-50

Predmety: Adult, Male, Antibodies, Monoclonal, Humanized / adverse effects, Antibodies, Monoclonal, Humanized / administration & dosage, Young Adult, Chemotherapy, Adjuvant / methods, B7-H1 Antigen / analysis, B7-H1 Antigen / antagonists & inhibitors, Humans, Neoadjuvant Therapy / adverse effects, Antineoplastic Agents, Immunological / administration & dosage, Antineoplastic Agents, Immunological / adverse effects, Aged, Aged, 80 and over, Head and Neck Neoplasms / mortality, Head and Neck Neoplasms / pathology, Squamous Cell Carcinoma of Head and Neck / pathology, Middle Aged, Head and Neck Neoplasms / drug therapy, Neoadjuvant Therapy / methods, Progression-Free Survival, Squamous Cell Carcinoma of Head and Neck / surgery, Intention to Treat Analysis, B7-H1 Antigen / metabolism, Treatment Outcome, Head and Neck Neoplasms / surgery, Squamous Cell Carcinoma of Head and Neck / drug therapy, Female, Chemotherapy, Adjuvant / adverse effects, Squamous Cell Carcinoma of Head and Neck / mortality

Popis súboru: application/pdf

Timing of ctDNA Analysis Aimed at Guiding Adjuvant Treatment in Colorectal Cancer

Autori: Tenna V. Henriksen Christina Demuth Amanda Frydendahl a ďalší

Zdroj: Henriksen, T V, Demuth, C, Frydendahl, A, Nors, J, Nesic, M, Rasmussen, M H, Larsen, O H, Jaensch, C, Løve, U S, Andersen, P V, Kolbro, T, Thorlacius-Ussing, O, Monti, A, Kildsig, J, Bondeven, P, Schlesinger, N H, Iversen, L H, Gotschalck, K A & Andersen, C L 2025, 'Timing of ctDNA Analysis Aimed at Guiding Adjuvant Treatment in Colorectal Cancer', Clinical Cancer Research, vol. 31, no. 9, pp. 1676-1685. https://doi.org/10.1158/1078-0432.CCR-24-3200

Predmety: Male, Adult, Aged, 80 and over, Time Factors, Liquid Biopsy, Liquid Biopsy/methods, Middle Aged, Prognosis, Colorectal Neoplasms/genetics, Circulating Tumor DNA, Circulating Tumor DNA/blood, Chemotherapy, Adjuvant, Biomarkers, Tumor, Humans, Female, Biomarkers, Tumor/genetics, Colorectal Neoplasms, Chemotherapy, Adjuvant/methods, Aged, Neoplasm Staging

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39976513

A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer

Autori: Sa-Nguansai, Sunatee Rattanasiri, Sasivimol Pornsuriyasak, Prapaporn a ďalší

Zdroj: Sci Rep
Sa-Nguansai, S, Rattanasiri, S, Pornsuriyasak, P, Numthavaj, P, McKay, G J, Attia, J & Thakkinstian, A 2025, 'A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer', Scientific Reports, vol. 15, 21696. https://doi.org/10.1038/s41598-025-05823-2

Predmety: Treatment Outcome, Protein Kinase Inhibitors/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, ErbB Receptors/antagonists & inhibitors, Immunotherapy/methods, Humans, Network Meta-Analysis as Topic, name=SDG 3 - Good Health and Well-being, Lung Neoplasms/drug therapy, Molecular Targeted Therapy/methods, Article, Chemotherapy, Adjuvant/methods, Randomized Controlled Trials as Topic

Popis súboru: application/pdf

Prístupová URL adresa: https://pure.qub.ac.uk/en/publications/470fbca2-94a7-49b8-b0ba-5e3fafed2560

The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer

Autori: Christian Jackisch Louiza Anastasiadou Sebastian Aulmann a ďalší

Zdroj: Breast Cancer Res Treat

Predmety: Adult, Aged, 80 and over, 0301 basic medicine, Gene Expression Profiling, Clinical Decision-Making, Breast Neoplasms, Middle Aged, Prognosis, Clinical Trial, Risk Assessment, Clinical Decision-Making [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Breast cancer, Neoplasm Recurrence, Local/pathology [MeSH], Breast Neoplasms/therapy [MeSH], Neoplasm Staging [MeSH], 21-gene assay, Adjuvant treatment, Neoplasm Recurrence, Local/genetics [MeSH], Ki-67 Antigen/metabolism [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Biomarkers, Tumor [MeSH], Risk Assessment/methods [MeSH], Registry, Breast Neoplasms/pathology [MeSH], Female [MeSH], Recurrence Score, Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Prognosis [MeSH], Gene Expression Profiling/methods [MeSH], Ki-67, Registries [MeSH], 03 medical and health sciences, Ki-67 Antigen, 0302 clinical medicine, Chemotherapy, Adjuvant, Biomarkers, Tumor, Humans, Female, Prospective Studies, Registries, Neoplasm Recurrence, Local, Aged, Neoplasm Staging

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38874685
https://repository.publisso.de/resource/frl:6518260

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer

Autori: Hatzipanagiotou, Maria Eleni Pigerl, Miriam Gerken, Michael a ďalší

Zdroj: Breast Cancer Res Treat

Predmety: 0301 basic medicine, ddc:610, Epidemiology, 610 Medizin, Triple Negative Breast Neoplasms, Breast Neoplasms, Combined Modality Therapy, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Triple negative breast cancer · Timing of adjuvant chemotherapy · Population-based cancer registry · Outcomes in TNBC · Routine practice data, Humans, Female, Female [MeSH], Timing of adjuvant chemotherapy, Triple Negative Breast Neoplasms/pathology [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Neoplasm Staging [MeSH], Triple negative breast cancer, Population-based cancer registry, Chemotherapy, Adjuvant/methods [MeSH], Outcomes in TNBC, Routine practice data, Combined Modality Therapy [MeSH], Breast Neoplasms/pathology [MeSH], Retrospective Studies, Neoplasm Staging

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38238552
https://repository.publisso.de/resource/frl:6522803
https://epub.uni-regensburg.de/55406/

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma

Autori: Jeffrey Weber Waqas Haque Svetomir N Markovic a ďalší

Zdroj: Oncologist
The oncologist, vol. 30, no. 3

Predmety: 03 medical and health sciences, 0302 clinical medicine, Humans, Oximes/administration & dosage, Oximes/therapeutic use, Oximes/pharmacology, Melanoma/drug therapy, Melanoma/genetics, Melanoma/pathology, Melanoma/mortality, Male, Female, Middle Aged, Imidazoles/therapeutic use, Imidazoles/administration & dosage, Imidazoles/pharmacology, Proto-Oncogene Proteins B-raf/genetics, Pyrimidinones/administration & dosage, Pyrimidinones/therapeutic use, Pyrimidinones/pharmacology, Pyridones/administration & dosage, Pyridones/therapeutic use, Pyridones/pharmacology, Retrospective Studies, Adult, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Chemotherapy, Adjuvant/methods, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Skin Neoplasms/genetics, Skin Neoplasms/mortality, Mutation, Disease-Free Survival, BRAF mutation, dabrafenib, melanoma, relapse-free survival, trametinib, Melanoma and Cutaneous Malignancies

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39560953
https://serval.unil.ch/notice/serval:BIB_A8A26871D41B
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A8A26871D41B1
https://serval.unil.ch/resource/serval:BIB_A8A26871D41B.P001/REF.pdf

PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study

Autori: Ballé, Judith Katharina Vetter, Martina Kenea, Tariku Wakuma a ďalší

Zdroj: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Predmety: Adult, Rural Population, Survival, Receptor, ErbB-2, Breast Neoplasms, Ethiopia, Aged [MeSH], Intrinsic subtypes, Receptor, ErbB-2/metabolism [MeSH], Ethiopia/epidemiology [MeSH], Breast Neoplasms/therapy [MeSH], PAM50, Africa, Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Prospective Studies [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Breast Cancer, Rural Population [MeSH], Immunohistochemistry [MeSH], Biomarkers, Tumor/metabolism [MeSH], Research, Prognosis [MeSH], Gene Expression Profiling [MeSH], Biomarkers, Tumor, Humans, Prospective Studies, RC254-282, Aged, ddc:610, Gene Expression Profiling, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Prognosis, Immunohistochemistry, Receptors, Estrogen, Chemotherapy, Adjuvant, Female, Receptors, Progesterone

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39256703
https://doaj.org/article/d1d8fe71a42b4c2c90d5d660b7d42f77
https://repository.publisso.de/resource/frl:6490436

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Autori: A. Gawaz I. Wolff L. Nanz a ďalší

Zdroj: Cancer Immunol Immunother

Predmety: Male, Aged, 80 and over, Skin Neoplasms, Research, Aged, 80 and over [MeSH], Melanoma, ≥ 75 years, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Elderly patients, Melanoma/drug therapy [MeSH], Female [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Melanoma/immunology [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Immune checkpoint inhibitor, Skin Neoplasms/mortality [MeSH], Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemotherapy, Adjuvant, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38969911
https://repository.publisso.de/resource/frl:6524688

On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer

Autori: Bruno Valentin Sinn Katharina Sychra Michael Untch a ďalší

Zdroj: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)

Predmety: Adult, Neoplasm, Residual, Receptor, ErbB-2, Biopsy, Breast Neoplasms, Disease-Free Survival, Breast cancer, Lymphocytes, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, TILs, RC254-282, Aged, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Serial biopsies, Middle Aged, Prognosis, Neoadjuvant Therapy, Ki-67 Antigen, Treatment Outcome, Receptors, Estrogen, Chemotherapy, Adjuvant, Neoadjuvant therapy, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Neoadjuvant Therapy/methods [MeSH], Ki-67 Antigen/metabolism [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Biopsy [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Lymphocytes, Tumor-Infiltrating/metabolism [MeSH], Neoplasm, Residual/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Lymphocytes, Tumor-Infiltrating/immunology [MeSH], Biomarkers, Tumor/metabolism [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Ki-67, Female, Receptors, Progesterone

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39317942
https://doaj.org/article/7254adee1eef456f91cca8c6f84490e2
https://repository.publisso.de/resource/frl:6503837

Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade

Autori: Miriam Mengoni Andreas Dominik Braun Mattes Simon Hinnerichs a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Middle Aged, Prognosis, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Body Composition, Humans, Female, Muscle, Skeletal, Tomography, X-Ray Computed, Melanoma, Immune Checkpoint Inhibitors, Melanoma/therapy [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Muscle, Skeletal/diagnostic imaging [MeSH], Skin Neoplasms/drug therapy [MeSH], Low skeletal muscle mass, Tomography, X-Ray Computed [MeSH], Male [MeSH], Muscle, Skeletal/pathology [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Body Composition [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Immunotherapy, Prognosis [MeSH], Skin Neoplasms/mortality [MeSH], Body composition, Retrospective Studies, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38796605
https://repository.publisso.de/resource/frl:6492801

The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents

Autori: Scheer, Monika Vokuhl, Christian Bauer, Sebastian a ďalší

Prispievatelia: Scheer, Monika Vokuhl, Christian Bauer, Sebastian a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Adult, Male, Medicin och hälsovetenskap, Cancer Research, Adolescent, Original Article – Clinical Oncology, Medizin, Adolescent [MeSH], Female [MeSH], Sarcoma, Synovial/therapy [MeSH], Radiotherapy, Adjuvant/methods [MeSH], Combined Modality Therapy/methods [MeSH], Adult [MeSH], Humans [MeSH], Middle Aged [MeSH], Pediatric sarcoma, Infant [MeSH], Male [MeSH], Time [MeSH], Adjuvant therapies, Young Adult [MeSH], Chemotherapy, Chemotherapy, Adjuvant/methods [MeSH], Soft-tissue sarcoma, Child [MeSH], Radiotherapy, Synovial sarcoma, Child, Preschool [MeSH], Medical and Health Sciences, Time, Sarcoma, Synovial, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Humans, Child, ddc:610, Infant, Middle Aged, Combined Modality Therapy, 3. Good health, Chemotherapy, Adjuvant, Child, Preschool, Female, Radiotherapy, Adjuvant, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit

Popis súboru: application/pdf; application/zip

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00432-021-03614-6.pdf
https://pubmed.ncbi.nlm.nih.gov/34272609
https://link.springer.com/content/pdf/10.1007/s00432-021-03614-6.pdf
https://www.ncbi.nlm.nih.gov/pubmed/34272609
https://link.springer.com/article/10.1007/s00432-021-03614-6
https://paperity.org/p/269661699/the-effect-of-adjuvant-therapies-on-long-term-outcome-for-primary-resected-synovial
https://pubmed.ncbi.nlm.nih.gov/34272609/
https://edoc.mdc-berlin.de/20483/
http://edoc.mdc-berlin.de/20483/1/20483oa.pdf
https://repository.publisso.de/resource/frl:6449888
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-459715

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study

Autori: S. Krajnak C. Schnatz K. Almstedt a ďalší

Prispievatelia: S. Krajnak C. Schnatz K. Almstedt a ďalší

Zdroj: Breast Cancer Res Treat

Predmety: Adult, Aged, 80 and over [MeSH], Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents/administration, Breast Neoplasms/therapy [MeSH], Neoadjuvant Therapy/methods [MeSH], Administration, Oral [MeSH], Cyclophosphamide/administration, Case-Control Studies [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Dose-Response Relationship, Drug [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Clinical Trial, Retrospective Studies [MeSH], Middle Aged [MeSH], Administration, Metronomic [MeSH], Oncology, Methotrexate/administration, Mastectomy [MeSH], Receptor, ErbB-2, 610 Medizin, Administration, Oral, Antineoplastic Agents, Breast Neoplasms, Kaplan-Meier Estimate, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Humans, Cyclophosphamide, Mastectomy, Aged, Aged, 80 and over, ddc:610, Dose-Response Relationship, Drug, Middle Aged, Neoadjuvant Therapy, Progression-Free Survival, 3. Good health, Methotrexate, Chemotherapy, Adjuvant, Case-Control Studies, Administration, Metronomic, Female

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s10549-020-05711-5.pdf
https://pubmed.ncbi.nlm.nih.gov/32495001
https://link.springer.com/content/pdf/10.1007/s10549-020-05711-5.pdf
https://pubmed.ncbi.nlm.nih.gov/32495001/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297707
https://link.springer.com/article/10.1007/s10549-020-05711-5
https://europepmc.org/article/PMC/PMC7297707
https://repository.publisso.de/resource/frl:6470722

Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients

Autori: Carolin Müller Ingolf Juhasz-Böss Gilda Schmidt a ďalší

Zdroj: Arch Gynecol Obstet

Predmety: Adult, ddc:610, Time Factors, Delaying factors, Breast Neoplasms, Gynecologic Oncology, Middle Aged, Female [MeSH], Aged [MeSH], Adult [MeSH], Humans [MeSH], Breast cancer, Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Neoadjuvant therapy, Young Adult [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/surgery [MeSH], Time to surgery, 3. Good health, Young Adult, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, 10. No inequality, Aged

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00404-020-05494-6.pdf
https://pubmed.ncbi.nlm.nih.gov/32170410
https://link.springer.com/content/pdf/10.1007/s00404-020-05494-6.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103004
https://www.ncbi.nlm.nih.gov/pubmed/32170410
https://pubmed.ncbi.nlm.nih.gov/32170410/
https://link.springer.com/article/10.1007/s00404-020-05494-6
https://repository.publisso.de/resource/frl:6466638

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Autori: Qiang Lan Curzio Rüegg David Barras a ďalší

Prispievatelia: Qiang Lan Curzio Rüegg David Barras a ďalší

Zdroj: Oncogene
Oncogene, vol. 38, no. 15, pp. 2814-2829

Predmety: Receptor, ErbB-2, Interferon Regulatory Factor-7, Nude, Local -- metabolism, Mice, SCID, Tumor -- metabolism, Breast Neoplasms -- drug therapy -- metabolism, Chemotherapy, Adjuvant -- methods, PATHWAY, Mice, 0302 clinical medicine, Mice, Inbred NOD, Antineoplastic Combined Chemotherapy Protocols, Receptor, ErbB-2 -- metabolism, TUMOR-INFILTRATING LYMPHOCYTES, Inbred BALB C, Genetics & Heredity, Mice, Inbred BALB C, Tumor, SITE, Neoadjuvant Therapy -- methods, Sciences bio-médicales et agricoles, Biomarkers, Tumor -- metabolism, Neoadjuvant Therapy, 3. Good health, Adjuvant -- methods, Doxorubicin -- pharmacology, Oncology, Chemotherapy, Adjuvant, Interferon Type I, Female, Cancers, Life Sciences & Biomedicine, Antineoplastic Combined Chemotherapy Protocols -- pharmacology, Receptor, EXPRESSION, Biochemistry & Molecular Biology, Receptor, erbB-2, 3101 Biochemistry and cell biology, Interferon-beta -- metabolism, ErbB-2 -- metabolism, Methotrexate -- pharmacology, Mice, Nude, Breast Neoplasms, SCID, Article, Cell Line, MECHANISMS, 03 medical and health sciences, Interferon Regulatory Factor-7 -- metabolism, 3211 Oncology and carcinogenesis, Cell Line, Tumor, Animals, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Biomarkers, Tumor/metabolism, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Chemotherapy, Adjuvant/methods, Doxorubicin/pharmacology, Epirubicin/pharmacology, Humans, Interferon Regulatory Factor-7/metabolism, Interferon Type I/metabolism, Interferon-beta/metabolism, Methotrexate/pharmacology, Neoadjuvant Therapy/methods, Neoplasm Recurrence, Local/metabolism, Receptor, ErbB-2/metabolism, Biomarkers, Tumor, Chemotherapy, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Neoplasm Recurrence, Local -- metabolism, Epirubicin, Science & Technology, IMMUNE-MEDIATED DORMANCY, Médecine pathologie humaine, 1103 Clinical Sciences, Cell Biology, Interferon-beta, Epirubicin -- pharmacology, Interferon Type I -- metabolism, Cancérologie, Neoplasm Recurrence, Methotrexate, Doxorubicin, CELLS, METASTASIS, Inbred NOD, Neoplasm Recurrence, Local, Biomarkers, RESISTANCE

Popis súboru: application/pdf; 1 full-text file(s): application/pdf

Prístupová URL adresa: https://www.nature.com/articles/s41388-018-0624-2.pdf
https://pubmed.ncbi.nlm.nih.gov/30546090
https://www.nature.com/articles/s41388-018-0624-2
https://www.nature.com/articles/s41388-018-0624-2.pdf
https://serval.unil.ch/notice/serval:BIB_94A8CCA9EF90
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283375/Details
https://researchportal.helsinki.fi/en/publications/type-i-interferonirf7-axis-instigates-chemotherapy-induced-immuno
https://doc.rero.ch/record/324696
https://lirias.kuleuven.be/handle/123456789/668229
https://doi.org/10.1038/s41388-018-0624-2
http://hdl.handle.net/10138/312010
https://serval.unil.ch/resource/serval:BIB_94A8CCA9EF90.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_94A8CCA9EF90
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_94A8CCA9EF908
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283375
http://doc.rero.ch/record/324696/files/rue_tia.pdf

Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

Autori: Ray-Coquard, Isabelle Cibula, David Mirza, Mansoor R a ďalší

Prispievatelia: Ray-Coquard, Isabelle Cibula, David Mirza, Mansoor R a ďalší

Zdroj: International Journal of Cancer, 146, 2, pp. 439-448

Predmety: Cancer Research, Indoles, Oncologie, Ovarian Neoplasms/therapy, Carboplatin, Placebos, tyrosine kinase inhibitor, 0302 clinical medicine, Ovarian Neoplasms/pathology, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel/adverse effects, nintedanib, Human health sciences, Medical Oncology - Radboud University Medical Center, Aged, 80 and over, Ovarian Neoplasms, Indoles/administration & dosage, Cytoreduction Surgical Procedures, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Progression-Free Survival, 3. Good health, ovarian cancer, Oncology, Chemotherapy, Adjuvant, Indoles/adverse effects, Female, Chemotherapy, Adjuvant/methods, Ovarian Neoplasms/mortality, Adult, Paclitaxel, overall survival, Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences, Protein Kinase Inhibitors/adverse effects, Sciences de la santé humaine, Young Adult, 03 medical and health sciences, Carboplatin/adverse effects, Chemotherapy, Adjuvant/adverse effects, Paclitaxel/administration & dosage, Ovary/surgery, Humans, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Protein Kinase Inhibitors/administration & dosage, Ovary, Carboplatin/administration & dosage, antiangiogenic, anti-angiogenic, Ovary/pathology, Follow-Up Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31381147
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/218867
https://doi.org/10.1002/ijc.32606
https://publicatt.unicatt.it/handle/10807/141114
https://boa.unimib.it/handle/10281/241889
https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902219141510847
https://moh-it.pure.elsevier.com/en/publications/final-results-from-gcigengotago-ovar-12-a-randomised-placebo-cont
https://www.ncbi.nlm.nih.gov/pubmed/31381147
https://europepmc.org/article/MED/31381147
https://hdl.handle.net/2066/218867
https://repository.ubn.ru.nl//bitstream/handle/2066/218867/218867.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32606
https://doi.org/10.1002/ijc.32606
https://hdl.handle.net/10281/241889
https://hdl.handle.net/2268/309155
https://doi.org/10.1002/ijc.32606
https://hdl.handle.net/10807/141114
https://doi.org/10.1002/ijc.32606

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data

Autori: Gabrielle Jongeneel Thomas Klausch Felice N. van Erning a ďalší

Prispievatelia: Gabrielle Jongeneel Thomas Klausch Felice N. van Erning a ďalší

Zdroj: Int J Cancer
Jongeneel, G, Klausch, T, van Erning, F N, Vink, G R, Koopman, M, Punt, C J A, Greuter, M J E & Coupé, V M H 2020, 'Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data', International Journal of Cancer, vol. 146, no. 11, pp. 2968-2978. https://doi.org/10.1002/ijc.32629

Predmety: Male, Cancer Research, treatment effect, Organoplatinum Compounds, Leucovorin, Fluorouracil/therapeutic use, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Colonic Neoplasms/drug therapy, Organoplatinum Compounds/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Journal Article, Humans, Comparative Study, Neoplasm Staging, Netherlands, Randomized Controlled Trials as Topic, Leucovorin/therapeutic use, real-world data, Research Support, Non-U.S. Gov't, randomized clinical trial, 3. Good health, adjuvant chemotherapy, colon cancer, Oncology, Chemotherapy, Adjuvant, Colonic Neoplasms, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Fluorouracil, Cancer Epidemiology, Chemotherapy, Adjuvant/methods

Popis súboru: application/pdf

Prístupová URL adresa: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.32629
https://pubmed.ncbi.nlm.nih.gov/31424568
https://europepmc.org/abstract/MED/31424568
https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2F1a7dcc03-5942-42d8-8f7c-9dcfb6f2071f
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32629
https://www.ncbi.nlm.nih.gov/pubmed/31424568
https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.32629
https://research.vumc.nl/en/publications/estimating-adjuvant-treatment-effects-in-stage-ii-colon-cancer-co
https://research.vumc.nl/en/publications/1a7dcc03-5942-42d8-8f7c-9dcfb6f2071f
https://dspace.library.uu.nl/handle/1874/441785
https://pure.amsterdamumc.nl/en/publications/165b2c6c-92a5-495b-9c48-1858a2358c11
https://doi.org/10.1002/ijc.32629

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)

Autori: Florian Gebauer Alexander Ioannis Damanakis Felix Popp a ďalší

Zdroj: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)

Predmety: Adult, Male, Pancreatic surgery, Leucovorin, Adenocarcinoma, Irinotecan, Leucovorin/administration, Liver Neoplasms/surgery [MeSH], Liver Neoplasms/mortality [MeSH], Pancreatic Neoplasms/pathology [MeSH], Liver metastasis, Progression-Free Survival [MeSH], Neoadjuvant Therapy/adverse effects [MeSH], Neoadjuvant Therapy/methods [MeSH], Adenocarcinoma/secondary [MeSH], Male [MeSH], Adenocarcinoma/drug therapy [MeSH], Liposomes [MeSH], Quality of Life [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Pancreatic Neoplasms/mortality [MeSH], Pancreatic Neoplasms/surgery [MeSH], Pancreatic cancer, Fluorouracil/administration, Oxaliplatin/administration, Female [MeSH], Adult [MeSH], Study Protocol, Humans [MeSH], Irinotecan/administration, Pancreatic Neoplasms/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Clinical trials, Liver Neoplasms/secondary [MeSH], Germany [MeSH], Chemotherapy, Chemotherapy, Adjuvant/adverse effects [MeSH], Adenocarcinoma/mortality [MeSH], Adenocarcinoma/surgery [MeSH], 03 medical and health sciences, Clinical Trials, Phase II as Topic, 0302 clinical medicine, Germany, Antineoplastic Combined Chemotherapy Protocols, Humans, Multicenter Studies as Topic, RC254-282, Liver Neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoadjuvant Therapy, Progression-Free Survival, 3. Good health, Oxaliplatin, Pancreatic Neoplasms, Chemotherapy, Adjuvant, Liposomes, Quality of Life, Female, Fluorouracil

Prístupová URL adresa: https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-08966-3
https://pubmed.ncbi.nlm.nih.gov/34794396
https://doaj.org/article/616c088826884c7d99c7984e35c6d4f5
https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-08966-3
https://pubmed.ncbi.nlm.nih.gov/34794396/
https://0-bmccancer-biomedcentral-com.brum.beds.ac.uk/track/pdf/10.1186/s12885-021-08966-3
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600696
https://repository.publisso.de/resource/frl:6462401

Tumor–stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

Autori: Hansen, Torben Frøstrup Kjær-Frifeldt, Sanne Lindebjerg, Jan a ďalší

Zdroj: Hansen, T F, Kjær-Frifeldt, S, Lindebjerg, J, Rafaelsen, S R, Jensen, L H, Jakobsen, A & Sørensen, F B 2018, ' Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy ', Acta Oncologica, vol. 57, no. 4, pp. 528-533 . https://doi.org/10.1080/0284186X.2017.1385841
Hansen, T F, Kjær-Frifeldt, S, Lindebjerg, J, Rafaelsen, S R, Jensen, L H, Jakobsen, A & Sørensen, F B 2018, 'Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy', Acta Oncologica, vol. 57, no. 4, pp. 528-533. https://doi.org/10.1080/0284186X.2017.1385841

Predmety: Adult, Male, Organoplatinum Compounds, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Colonic Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Chemotherapy, Humans, Adjuvant/methods, Organoplatinum Compounds/administration & dosage, Capecitabine, Stromal Cells/pathology, Aged, Neoplasm Recurrence, Local/epidemiology, Aged, 80 and over, Local/epidemiology, Neoadjuvant Therapy/methods, Middle Aged, Prognosis, Neoadjuvant Therapy, 3. Good health, Oxaliplatin, Neoplasm Recurrence, Capecitabine/administration & dosage, Chemotherapy, Adjuvant, 13. Climate action, Colonic Neoplasms, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local, Stromal Cells, Chemotherapy, Adjuvant/methods

Popis súboru: application/pdf

Prístupová URL adresa: https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2017.1385841?needAccess=true
https://pubmed.ncbi.nlm.nih.gov/28980848
https://pubmed.ncbi.nlm.nih.gov/28980848/
https://www.ncbi.nlm.nih.gov/pubmed/28980848
https://portal.findresearcher.sdu.dk/da/publications/tumor-stroma-ratio-predicts-recurrence-in-patients-with-colon-can
https://europepmc.org/abstract/MED/28980848
https://www.tandfonline.com/doi/full/10.1080/0284186X.2017.1385841
https://findresearcher.sdu.dk:8443/ws/files/142729618/Tumor_stroma_ratio_predicts_recurrence_in_patients_with_colon_cancer_treated_with_neoadjuvant_chemotherapy.pdf
https://portal.findresearcher.sdu.dk/da/publications/a21741f9-ed2e-4b3b-918e-08febb28da5a
https://doi.org/10.1080/0284186X.2017.1385841
https://findresearcher.sdu.dk:8443/ws/files/142729618/Tumor_stroma_ratio_predicts_recurrence_in_patients_with_colon_cancer_treated_with_neoadjuvant_chemotherapy.pdf
https://pure.au.dk/portal/en/publications/e072fa3b-7bc6-45aa-876d-a3d6dd578dce
https://doi.org/10.1080/0284186X.2017.1385841

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.

Autori: Ray-Coquard, Isabelle Cibula, David Mirza, Mansoor R a ďalší

Zdroj: International Journal of Cancer, 146 (2), 439 - 448 (2020-01-15)

Predmety: antiangiogenic, nintedanib, ovarian cancer, overall survival, tyrosine kinase inhibitor, Indoles, Placebos, Protein Kinase Inhibitors, Carboplatin, Paclitaxel, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Carboplatin/adverse effects, Chemotherapy, Adjuvant/adverse effects, Chemotherapy, Adjuvant/methods, Cytoreduction Surgical Procedures, Female, Follow-Up Studies, Humans, Indoles/administration & dosage, Indoles/adverse effects, Middle Aged, Neoplasm Staging, Ovarian Neoplasms/mortality, Ovarian Neoplasms/pathology, Ovarian Neoplasms/therapy, Ovary/pathology, Ovary/surgery, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Progression-Free Survival, Protein Kinase Inhibitors/administration & dosage, Protein Kinase Inhibitors/adverse effects, Young Adult, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Ovarian Neoplasms, Ovary, Oncology, Cancer Research, Human health sciences, Sciences de la santé humaine, Oncologie

Relation: https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32606; urn:issn:0020-7136; urn:issn:1097-0215

Prístupová URL adresa: https://orbi.uliege.be/handle/2268/309155

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: a survey by the European Retinoblastoma group (EURbG)

Autori: Nikolaos E. Bechrakis Maja Beck Popovic Ida Russo a ďalší

Prispievatelia: Nikolaos E. Bechrakis Maja Beck Popovic Ida Russo a ďalší

Zdroj: RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
instname
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
PEDIATRIC BLOOD & CANCER
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Dittner-Moormann, S, Reschke, M, Abbink, F C H, Aerts, I, Atalay, H T, Fedorovna Bobrova, N, Biewald, E, Brecht, I B, Caspi, S, Cassoux, N, Castela, G, Diarra, Y, Duncan, C, Ebinger, M, Garcia Aldana, D, Hadjistilianou, D, Kepák, T, Klett, A, Kiratli, H, Maka, E, Opocher, E, Pawinska-Wasikowska, K, Rascon, J, Russo, I, Rutynowska-Pronicka, O, Sábado Álvarez, C, Pacheco, S S R, Svojgr, K, Timmermann, B, Vishnevskia-Dai, V, Eggert, A, Ritter-Sovinz, P, Bechrakis, N E, Jenkinson, H, Moll, A, Munier, F L, Popovic, M B, Chantada, G, Doz, F & Ketteler, P 2021, 'Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)', Pediatric Blood and Cancer, vol. 68, no. 6, e28963. https://doi.org/10.1002/pbc.28963
Pediatric blood & cancer, vol. 68, no. 6, pp. e28963
Pediatric blood & cancer., Hoboken : Wiley, 2021, vol. 68, iss. 6, art. no. e28963, p. [1-9].

Predmety: Retinal Neoplasms, Medizin, childhood cancer, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors, chemotherapy, Enquestes, Eye Enucleation, metastasis, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Surveys and Questionnaires, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo, Antineoplastic Combined Chemotherapy Protocols, biomarker, Humans, Child, radiotherapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy, Retina - Càncer - Radioteràpia, RB1 gene, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires, Retinoblastoma, DISEASES::Neoplasms::Neoplasms::Neoplasms::Neoplasms::Neoplasms by Site::Eye Neoplasms::Retinal Neoplasms::Retinoblastoma, ENFERMEDADES::neoplasias::neoplasias::neoplasias::neoplasias::neoplasias por localización::neoplasias del ojo::neoplasias de la retina::retinoblastoma, Prognosis, Combined Modality Therapy, 3. Good health, Retina - Càncer - Quimioteràpia, Europe, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Chemotherapy, Adjuvant/methods, Child, Preschool, Combined Modality Therapy/methods, Radiotherapy, Adjuvant/methods, Retinal Neoplasms/pathology, Retinal Neoplasms/therapy, Retinoblastoma/pathology, Retinoblastoma/therapy, Chemotherapy, Adjuvant, Radiotherapy, Adjuvant, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado

Popis súboru: application/pdf

Prístupová URL adresa: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/pbc.28963
https://pubmed.ncbi.nlm.nih.gov/33720495
http://hdl.handle.net/10668/17353
https://hdl.handle.net/11351/7617
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19278
https://hdl.handle.net/20.500.12530/67926
https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19278
https://www.authorea.com/users/382208/articles/498172-adjuvant-therapy-of-histopathological-risk-factors-of-retinoblastoma-in-europe-a-survey-by-the-european-retinoblastoma-group-eurbg
https://d197for5662m48.cloudfront.net/doi/full/10.22541/au.160761774.49039452/v1
https://epublications.vu.lt/object/elaba:87515578/index.html
https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2Feb3016b6-108d-4607-a6e6-5c97f4e5debb
https://www.ncbi.nlm.nih.gov/pubmed/33720495
https://research.vumc.nl/en/publications/adjuvant-therapy-of-histopathological-risk-factors-of-retinoblast
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28963
https://www.muni.cz/vyzkum/publikace/1786843
https://avesis.gazi.edu.tr/publication/details/414c08df-97af-439a-8b1b-70960bc95e9c/oai
https://research.vumc.nl/en/publications/eb3016b6-108d-4607-a6e6-5c97f4e5debb
https://serval.unil.ch/resource/serval:BIB_C745699D2ADF.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_C745699D2ADF
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_C745699D2ADF5
https://hdl.handle.net/10668/17353
https://onlinelibrary.wiley.com/doi/10.1002/pbc.28963
https://ruj.uj.edu.pl/xmlui/handle/item/290327
https://repository.vu.lt/VU:ELABAPDB87515578&prefLang=en_US